Table 1.
Univariate and multivariate analyses for relapse‐free survival of 376 female patients (2001–2008) treated at Kumamoto University Hospital
| Variables | Categories | n | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | P‐value† | HR | 95% CI | P‐value† | |||
| GANP | IHC 0–1 vs. IHC 2–3 | 170/206 | 2.37 | 1.27–4.42 | 0.007 | 2.70 | 1.42–5.13 | 0.002 |
| Other covariates | ||||||||
| Menopause | Post. vs. pre | 123/253 | 0.62 | 0.34–1.13 | 0.120 | Excluded | – | – |
| Tumor size | ≥2 cm vs. <2 cm | 162/214 | 2.66 | 1.43–4.97 | 0.002 | 1.61 | 0.79–3.30 | 0.19 |
| Nodal status | Positive vs. negative | 168/204‡ | 2.47 | 1.36–4.49 | 0.003 | 1.84 | 0.96–3.54 | 0.07 |
| Nuclear grade | 2–3 vs. 1 | 168/204§ | 3.28 | 1.68–6.41 | 0.001 | 1.26 | 1.06–1.49 | 0.01 |
| ERα | Positive vs. negative | 298/78 | 0.24 | 0.13–0.44 | <0.001 | 0.32 | 0.12–0.81 | 0.02 |
| PgR | Positive vs. negative | 255/121 | 0.33 | 0.18–0.60 | <0.001 | 0.82 | 0.32–2.09 | 0.68 |
| Her2 | Positive vs. negative | 55/321 | 1.54 | 0.74–3.21 | 0.250 | 0.59 | 0.26–1.35 | 0.21 |
| Ki67 | Positive vs. negative | 179/181¶ | 3.45 | 1.70–7.00 | 0.001 | 2.13 | 1.00–4.54 | 0.05 |
Hazard ratios (HR) and 95% confidence intervals (CI) were estimated by Cox proportional hazard model. † P‐values were based on two‐sided test. ‡Four cases were of unknown nodal status. §Four cases were of unknown nuclear grade. ¶Sixteen cases were of unknown Ki67 status. Cut‐off values for estrogen receptor α (ERα), progesterone receptor (PgR), human epidermal growth factor receptor 2 (Her2), and Ki67 were determined based on the American Society of Clinical Oncology/College of American Pathologists guideline (2013). IHC, immunohistochemistry.